Debt Financing Funded Biotechnology Startups
The 50 debt financing rounds listed here span late 2021 through October 2022, covering biotechnology companies across the United States, Europe, Israel, an…
The 50 debt financing rounds listed here span late 2021 through October 2022, covering biotechnology companies across the United States, Europe, Israel, and Asia. Deal sizes vary by several orders of magnitude—from $50K (Therabene, Mansfield, Massachusetts; Cytogel Pharma, Darien, Connecticut) to $100M (InSightec, Tirat Carmel, Israel)—with a cluster of mid-range rounds above $20M anchored by TScan Therapeutics ($60M, September 2022), Antheia ($40M, June 2022), and Orchestra BioMed ($40M, July 2022). Two rounds—Apollo Intelligence (Stamford, Connecticut) and onCyt (Dubendorf, Switzerland)—carried undisclosed amounts.
Massachusetts and California each host seven companies in the set, making them the dominant US geographies. Switzerland is the leading non-US location with five entries, followed by Israel (three entries, including the largest deal) and Italy (two). The records run from December 1, 2021 (Cannara Biotech, Montréal) through October 20, 2022 (Inceptor Bio, Raleigh, North Carolina), offering a roughly eleven-month window into debt activity across early- and growth-stage biotech.
Most recent rounds
50 shownRelated listings
Frequently asked
What are the largest biotech debt rounds in this dataset?
InSightec (Tirat Carmel, Israel) leads at $100M, closed September 1, 2022. TScan Therapeutics (Waltham, Massachusetts) follows at $60M on September 12, 2022. Antheia (Menlo Park, California) and Orchestra BioMed (New Hope, Pennsylvania) each raised $40M in June and July 2022 respectively, and SeLux Diagnostics (Charlestown, Massachusetts) closed a $30M round on June 1, 2022.
Which US metro areas have the most biotech debt activity in this set?
Massachusetts cities are the most concentrated cluster: Boston (DermBiont, Nanoview Biosciences), Waltham (TScan Therapeutics), Charlestown (SeLux Diagnostics), Framingham (Variantyx), Beverly (Prospective Research), and Mansfield (Therabene) all appear. California follows, with Menlo Park (Vortex Biosciences, Antheia), South San Francisco (MiNDERA Corporation, Secure Transfusion Services), Sunnyvale (Tosk), and Oxnard (Cure Pharmaceutical) represented.
How small do biotech debt rounds get in this segment?
The floor in this set is $50K, recorded by Therabene (Mansfield, Massachusetts, October 2022) and Cytogel Pharma (Darien, Connecticut, July 2022). Five additional companies—ArcoScreen, Tosk, GliaPharm, FGen, and MaxWell Biosystems—each closed at $100K, indicating that debt instruments at this stage are used across a very wide capital range.
How significant is the international footprint in biotech debt financing here?
Non-US companies account for roughly a quarter of the 50 entries. Switzerland leads with five companies spread across Basel (FGen, MaxWell Biosystems), Lausanne (ArcoScreen), Geneva (GliaPharm), and Dubendorf (onCyt). Israel contributes three entries including the dataset's largest round (InSightec, $100M), and Italy, Germany, the UK, Canada, India, and Singapore each contribute one.
Which US states outside California and Massachusetts appear most in the data?
New York has four entries: Oculogica, H1, Click Therapeutics, and Girihlet (Brooklyn). Connecticut contributes three—Apollo Intelligence (Stamford), Cytogel Pharma (Darien), and Shoreline Biome (Farmington). North Carolina (Inceptor Bio in Raleigh, Lucerno Dynamics in Cary) and Tennessee (AgGenetics in Murfreesboro, SOMAVAC Medical Solutions in Memphis) each have two.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.